Novartis AG NVS.N, NVS is expected to show a rise in quarterly revenue when it reports results on April 29 for the period ending March 31 2025
The Basel Basel-stadt-based company is expected to report a 10.4% increase in revenue to $13.058 billion from $11.83 billion a year ago, according to the mean estimate from 4 analysts, based on LSEG data.
LSEG's mean analyst estimate for Novartis AG is for earnings of $2.13 per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 6 "hold" and 3 "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Novartis AG is $110.00, below its last closing price of $111.17.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Dec. 31 2024 | 1.83 | 1.81 | 1.98 | Beat | 9.3 |
Sep. 30 2024 | 1.97 | 1.96 | 2.06 | Beat | 5.1 |
Jun. 30 2024 | 1.88 | 1.89 | 1.97 | Beat | 4.2 |
Mar. 31 2024 | 1.63 | 1.69 | 1.80 | Beat | 6.8 |
Dec. 31 2023 | 1.72 | 1.69 | 1.53 | Missed | -9.2 |
Sep. 30 2023 | 1.70 | 1.70 | 1.83 | Beat | 7.9 |
Jun. 30 2023 | 1.69 | 1.68 | 1.83 | Beat | 8.7 |
Mar. 31 2023 | 1.55 | 1.55 | 1.71 | Beat | 10.5 |
This summary was machine generated April 25 at 06:43 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。